U.S. markets closed

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
99.51+6.88 (+7.43%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close92.63
Open96.00
Bid99.54 x 1300
Ask102.00 x 1000
Day's Range92.68 - 100.00
52 Week Range13.00 - 122.81
Volume970,894
Avg. Volume881,564
Market Cap5.813B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.83
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est59.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors

    CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today announced that it has agreed to sell 2,795,700 shares of its common stock to certain institutional investors in a private placement. The Company anticipates aggregate gross proceeds from the offering will be approximately $260 million, before deducting fees to the placement agents and other estimated offering expenses payable by the Company, based on the offering price of $93.00 per share, representing an approximately 10% discount to the 5-day volume weighted average share price. The financing syndicate includes Perceptive Advisors, Farallon Capital, Casdin Capital, Redmile Group and Cormorant Asset Management, among others. The closing is anticipated to occur on January 21, 2021, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to support clinical development, to pursue strategic partnerships and general corporate purposes. J.P. Morgan acted as lead placement agent and William Blair acted as joint placement agent. The securities are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Company has agreed to file a resale registration statement with the Securities and Exchange Commission (the “SEC”), for purposes of registering the resale of the shares of common stock issued or issuable in connection with the offering. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. Forward Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including without limitation, statements regarding the expected timing for the closing of the private placement and the expected use of proceeds from the private placement. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. These risks and uncertainties include risks relating to the Company’s inability, or the inability of the purchasers, to satisfy the conditions to closing for the private placement and those identified under the heading “Risk Factors” in Company’s Annual Report on Form 10-K for the year ended December 31, 2019, the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and other filings the Company makes with the SEC. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in the Company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, the Company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contacts: Investors:Chelcie ListerTHRUST Strategic Communicationschelcie@thrustsc.com Media:Dan Budwick1ABdan@1abmedia.com

  • 7 CRISPR Stocks for the Future of Medicine
    InvestorPlace

    7 CRISPR Stocks for the Future of Medicine

    In June 2012, the world changed forever. You probably didn’t even notice. It was in that month’s issue of the Science journal that U.C. Berkeley professor Jennifer Doudna and Umea University professor Emmanuelle Charpentier unveiled what the scientific community has since labeled the “scientific breakthrough of the century.” The breakthrough: CRISPR-Cas9 genetic editing systems.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Doudna and Charpentier invented a pair of “scissors” – called CRISPR-Cas9 systems – to cut specific DNA threads and modify genes inside of living organisms. How? Bacteria. Doudna and Charpentier noted a naturally occurring genome editing system in bacteria, wherein bacteria capture snippets of DNA from invading viruses and create new DNA segments called CRISPR arrays that are designed specifically to recognize the DNA of the invading virus. Thus, once the virus attacks the bacteria again, the CRISPR array recognizes the virus’ DNA, and deploys a Cas9 enzyme to “cut” the invading DNA, rendering the virus ineffective. It’s pure genius. Doudna and Charpentier figured out how to harness the power of this genius genomic editing system in bacteria and how to use it for anything. Essentially, the two invented a way to engineer small CRISPR arrays paired to a target sequence of DNA in a genome. That CRISPR array is then injected into the genome, where it binds to the target sequence and uses a Cas9 enzyme to cut the DNA at the targeted location. Sign Up Here to Keep Up With Luke’s Hypergrowth Stock Picks Once the DNA is cut, researchers can insert, remove, and/or edit genetic material in that DNA sequence as they please. If that sounds like a big deal, it’s because it is… Source: Shutterstock Doudna and Charpentier’s breakthrough discovery has since ushered in a new era of genetic engineering, wherein some of the smartest people in some of the most prestigious labs in the world are using CRISPR-Cas9 systems to life-changing affect. For example, the following use-cases apply: Cure diseases like cystic fibrosis, cancer, and sickle cell disease. Create sustainable biofuels. Engineer more robust, pest- and disease-resistant crops. And much more. Indeed, the potential applications of CRISPR-Cas9 genetic editing systems are endless. Because every living thing has DNA, meaning that a perfect CRISPR-Cas9 system could theoretically change anything about anything. But… if true… then why aren’t CRISPR-Cas9 systems everywhere? Why hasn’t cancer been cured? Why are crops still dying from pests and disease? After all, it’s been eight years since CRISPR-Cas9 systems were invented. Where are the real-world results? The answer: Stuck behind an insurmountable mountain of genetic data. CRISPR-Cas9 genetic editing is a complex science. You are, after all, cutting DNA sequences – which, to do effectively and without producing unwanted side effects, requires precision and accuracy. Precision and accuracy are achieved through data. If researchers have all the data on all genetic things in the world, they know exactly where to cut, when to cut, what to inject after they cut, and how to patch it all up when they’re done. Unfortunately, that’s a big “if” which has proven to be an enormous obstacle to effectively administering CRISPR-Cas9 systems… The human genome alone is made up of 20,000 genes and more than 3 billion base pairs. And everyone is different. Plus, every animal is different. Every crop is different. Everything is different. You get the picture. The enormity of genetic data in the world is unparalleled. Up until recently, scientists simply had no way of effectively combing through and understanding all of that genetic data. Then artificial intelligence (AI) showed up to the party. In essence, breakthroughs in artificial intelligence over the past few years have enabled machines and algorithms to effectively comb through and help researchers make sense of all the genetic data at their fingertips. Case-in-point: researchers at the Wellcome Sanger Institute have created a machine learning model that – thanks to ingesting data from over a billion mutational outcomes from CRISPR-Cas9 systems – can effectively predict the exact mutations from CRISPR-Cas9 systems from just the sequence of the target DNA, thereby enabling researchers to prevent unwanted side effects of such genetic engineering. Dozens of these of AI models have popped up over the past few years. They are slowly, but surely, enabling scientists to take the promising concept of CRISPR-Cas9 genetic editing systems and turn them into a disruptive reality. Make no mistake. This transition will happen on a widespread scale over the next decade. As it does, humans will take a huge leap forward when it comes to curing disease, improving health, fortifying food safety, and much, much more. The implications are enormous – so, too, will be the returns in genetic editing stocks. There are only a handful of high-quality, publicly traded genetic editing stocks out there today. All of them are worth a good hard look. In the CRISPR-Cas9 world, you have what I like to call the “Big 3” between CRISPR Therapeutics (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), and Intellia Therapeutics (NASDAQ:NTLA). CRISPR was founded by Emmanuelle Charpentier – the French microbiologist who co-invented CRISPR-Cas9 systems. It is the largest and most well-established genetic editing company in the world, with a robust and mature gene editing therapy pipeline focused on curing sickle cell disease and delivering immune-oncology cell therapies. Editas has an ocular focus, with a portfolio of gene-editing therapies aimed at eradicating inherited retinal disease (i.e. genetic blindness). Intellia, meanwhile, takes a more specialized approach, having developed a portfolio of genetic editing therapies aimed at curing “rarer” diseases like Hereditary Angioedema, Acute Myeloid Leukemia, and Transthyretin Amyloidosis. Beam Therapeutics (NASDAQ:BEAM) is worth a look, too, as is Cellectis (NASDAQ:CLLS). Beam employs a unique genetic editing approach called “base” editing, which is less intrusive than traditional CRISPR-Cas9 systems and possesses substantially lower risk of off-target effects. Cellectis uses a non-CRISPR gene editing technology called TALEN to eradicate cancer cells. Genomic medicine company Sangamo Therapeutics (NASDAQ:SGMO) also deserves some attention. Last, but not least, you have a small company by the name of Calyxt (NASDAQ:CLXT) that is using TALEN gene editing technology to create a new generation of superior crops. Between these seven genetic editing pioneers, you have the highest quality and widest exposure to the biggest scientific breakthrough of the century. Don’t let this truly once-in-a-lifetime opportunity pass you by… On the date of publication, Luke Lango did not have (either directly or indirectly) any positions in the securities mentioned in this article. The New Daily 10X Stock Report: Dozens of triple-digit winners, peak gains as high as 926%… 1,326%… and 1,392%. InvestorPlace’s bold new initiative delivers one breakthrough stock recommendation every trading day, targeting gains of 5X… 10X… even 15X and beyond. Now, for a limited time, you can get in for just $19. Click here to find out how. In addition, you can sign up for Luke’s free Hypergrowth Investing newsletter. Click here to sign up now. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner It doesn’t matter if you have $500 in savings or $5 million. Do this now. The post 7 CRISPR Stocks for the Future of Medicine appeared first on InvestorPlace.

  • Barrons.com

    With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting Edge

    Stocks of start-ups wielding tools like Crispr-Cas9 that allow companies to edit DNA and attack genetic diseases and cancer are suddenly hot. But the science is moving with incredible speed and the competition is rising.